Join Growin Stock Community!

Gilead sciences inc(GILD.US AI Earnings Summary)

US StockHealthcare
No presentation for GILD

GILD AI Earnings Summary (In-Depth)

Last updated: 2026-10-29 (US time)

2026 Q3

Core Highlights

HIV and New Products Drive Growth; Full-Year Sales Guidance Raised

  • Stock Price Reaction: Gilead Sciences announced its earnings after the bell on October 29, 2026, EST. Driven by an 18% YoY growth in its flagship HIV business, both adjusted EPS and full-year sales guidance outperformed, pushing the stock price up as much as 2.9% to $170.40 in after-hours trading (10/29 EST). During the regular trading session (10/29 EST), the stock closed at $165.61 (+4.03%).
  • Market Expectations: Non-GAAP diluted EPS for the quarter was $2.55, beating the market consensus of $2.17 by approximately 17.5%. The significant EPS beat was primarily due to strong sales of the flagship HIV product Biktarvy (up 10% YoY to approx. $4.1B), which drove the overall HIV business up 18% YoY to approx. $6.2B, coupled with effective operating expense management.
  • Against Last Quarter's Guidance: During the previous quarter's (2026 Q2) earnings call, only full-year guidance was provided, with no specific guidance for Q3. Therefore, actual Q3 figures cannot be directly compared to full-year guidance. Non-GAAP diluted EPS of $2.55 exceeded the market consensus of $2.17 by approximately 17.5%.
  • In One Sentence: Gilead Sciences recorded its fastest base business growth in over a decade this quarter, driven by strong demand for its flagship HIV drug Biktarvy and the new drug Yeztugo, with the market responding with an after-hours surge of up to 2.9%.

The release followed the regular-session close on October 29, 2026. The pre-release close was $165.61; the session’s 4.03% rise preceded the release. On October 30, the first full post-release session, the stock closed at $170.68, up approximately 3.06% from the pre-release close.

Quarterly Highlights

This quarter's Non-GAAP EPS of $2.55 exceeded the market consensus of $2.17 by approximately 17.5%, primarily driven by explosive growth in the HIV business, with the base business recording its strongest YoY growth in a decade.

  1. Base Business Records Strongest Growth in a Decade: 2026 Q3 base business sales (excluding Veklury) reached $8.2B, a 16% YoY increase, the highest growth rate since 2015. Total product sales including Veklury were $8.3B, up 13% YoY and 9% QoQ. Full-year base business sales guidance was raised to $30.7B–$31.0B, an upward revision of approximately $1.65B at the midpoint compared to the initial guidance at the start of the year.

  2. HIV Business Up 18% YoY, Biktarvy Market Share Hits Record High: Total HIV sales reached $6.25B, a YoY increase of nearly $1B, the strongest YoY growth since 2018 Q4, driven by higher average realized price, demand growth, and favorable inventory dynamics. Biktarvy sales were $4.1B, up 10% YoY, with a record 53% share of the US treatment market.

  3. HIV Prevention (PrEP) Business Nearly Doubles, Yeztugo Establishes Market Leadership: PrEP sales nearly doubled YoY, far outperforming the overall US PrEP market growth of 14%. Yeztugo quarterly sales reached $305M, up 31% QoQ, becoming the leading brand for long-acting injectable PrEP in the US, with full-year sales expected to reach approximately $1B. Descovy sales were $1B, up 49% YoY. Together, Yeztugo and Descovy account for 50% of the US PrEP market, with annualized sales reaching $4B.

  4. Trodelvy Up 42% YoY, Reaching $2B Annualized Sales Scale: Trodelvy quarterly sales were $506M, up 42% YoY and 11% QoQ, driven by strong demand in triple-negative and HR+/HER2- metastatic breast cancer, with contributions from both the US and Europe. This quarter also saw European approval for Trodelvy in combination with pembrolizumab for first-line PD-L1 positive metastatic TNBC, further expanding the indications.

  5. Non-GAAP Product Gross Margin Increases to 88%, Operating Margin Maintained at 50%: Gross margin increased by 2 percentage points compared to 86% in 2025 Q3, primarily benefiting from the elimination of TAF-related royalty obligations that expired in November 2025. Non-GAAP operating margin remained at 50%, with Non-GAAP diluted EPS at $2.55. Excluding the one-time contribution of approx. $0.25 per share from IP asset sales in 2025 Q3, EPS grew approximately 15% YoY in real terms.

  6. Livdelzi Up 93% YoY, Liver Disease Business Expands Steadily: Livdelzi (for primary biliary cholangitis, PBC) quarterly sales were $203M, up 93% YoY and 21% QoQ, continuing to consolidate its leadership in the US second-line PBC market. Total liver disease sales reached $927M, up 13% YoY.

  7. IRA Pricing Impact Quantified, 2028 Outlook Remains Positive: The Centers for Medicare & Medicaid Services (CMS) set the Maximum Fair Price for Biktarvy at $2,600 per 30-day supply, a discount of approximately 38% off the list price. Management preliminary estimates the net revenue impact on Biktarvy in 2028 to be approximately $1.5B, but expects total 2028 HIV revenue, total product sales, and EPS to still grow compared to 2027.

  8. Steady Shareholder Returns, Manageable Financial Leverage: In 2026 Q3, approximately $1.4B was returned to shareholders, including $1B in dividends and $370M in share repurchases. Total returns for the first three quarters accounted for approximately 40% of free cash flow. The adjusted debt-to-adjusted EBITDA ratio remained at approximately 1.79x.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer